Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Axsome Therapeutics

CRISPR Therapeutics is awaiting approval for a potential multi-billion product. Axsome Therapeutics has several clinical and regulatory milestones ahead.

Prediction: These 2 Stocks Could Double In the Next Year

Carnival

Demand is back for Carnival's cruises, and the company is progressing along the road to profitability. CRISPR Therapeutics may be months away from a regulatory decision -- and a potential product launch.

2 Supercharged Stocks to Buy With $100

Vertex Pharmaceuticals

Vertex Pharmaceuticals is one of the few gene-editing companies that is already profitable. Brookfield Renewable Partners offers exposure to diverse parts of the renewable energy landscape.

2 Top Trends to Invest $5,000 in Right Now

Teladoc

CRISPR Therapeutics may be close to launching its very first product. Teladoc Health has shifted its strategy to favor its goal of profitability.

Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health

Cathie Wood just sold quite a few shares of CRISPR Therapeutics, likely at a profit. The biotech could launch its first medicine in a year.

Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It

Regulatory marketing authorization filings for its lead drug candidate were submitted to U.S. and international bodies. Three weeks separate the U.S. filings from that of a competitor's product.

Crispr Therapeutics: Hold Until A Firmer Decision Date

Patients are currently being enrolled by CRISPR Therapeutics AG in a potentially pivotal single-arm phase 2 study using CTX-110 for the treatment of patients with large B-cell lymphoma. CTX-110 was successful in patients with LBCL in phase 1 CARBON study; patients who received CTX-110 at DL≥3 resulted in an ORR of 67% and CR rate of 41%.

Crispr Therapeutics: Potential Beyond Current BLA Filing Of Exa-Cel

Airbnb

Airbnb's unique business model will continue to set it apart in the travel and tourism industry. CRISPR Therapeutics' near-term outlook is quite favorable.

2 Stocks You'll Be Glad You Bought at These Prices

Nano-X Imaging

Shares of CRISPR Therapeutics and Nanox have risen sharply in 2023. CRISPR Therapeutics is developing a slate of experimental gene therapies, and the first could earn approval this year.

2 Soaring Growth Stocks That Could Rocket Even Higher

CRISPR Therapeutics AG (NASDAQ:CRSP ) JMP Securities Life Sciences Conference May 15, 2023 11:30 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Silvan Türkcan - JMP Securities Silvan Türkcan Thanks. Welcome back.

CRISPR Therapeutics AG (CRSP) Presents at JMP Securities Life Sciences Conference (Transcript)

CRISPR Therapeutics AG (NASDAQ:CRSP ) Bank of America Securities 2023 Health Care Conference May 9, 2023 1:40 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the morning session of the BofA Healthcare Conference. I'm Geoff Meacham.

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)

BioXcel Therapeutics

Verve Therapeutics

A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.

Why These 3 Nasdaq Stocks Were Glowing Green This Week

CRISPR Therapeutics reported 2023 Q1 earnings yesterday. The biotech's Q1 report was full of good news for shareholders.

Why CRISPR Therapeutics Stock Is on Fire Today

CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.

CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to loss of $2.32 per share a year ago.

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates

-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)-

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Growth stocks have been in rally mode for the majority of 2023. Gene-editing pioneer CRISPR Therapeutics has been among the group's top performers.

1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May

Medtronic

Pfizer

Two of these players are approaching the finish line with big potential products. And the third just signed a deal that shows its commitment to artificial intelligence.

3 Top Healthcare Stocks to Buy in May

ZUG, Switzerland and CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in May.

CRISPR Therapeutics to Participate Upcoming Investor Conferences

Beam Therapeutics

Twist Bioscience Corp

Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.

3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers

Two months after my last bullish note on Crispr Therapeutics, predicting a bull run, the share price has barely budged. I find this surprising. Crispr and partner Vertex have now submitted their biologics license application to the FDA for approval of Sickle Cell Disease therapy.

Crispr Therapeutics: Upside Likely Coming Now That Exa-Cel Is With FDA

CRISPR Therapeutics is on the precipice of having its first FDA-approved therapy. The upstart biotech company is also working on a range of other potential therapies.

Is It Too Late to Buy CRISPR Stock?

Its gene-editing therapies could be game changers that revolutionize healthcare. If exa-cel is approved, it would serve as a functional cure for two challenging diseases.

Why CRISPR Therapeutics Just Became an Even Better Buy

Intellia Therapeutics

Investors have shown keen interest in biotech after Johnson & Johnson's (NYSE: JNJ ) impressive earnings beat that topped Wall Street's expectations. The earnings beat reignited enthusiasm for biotech stocks, prompting investors to search for the next big players.

3 Biotech Stocks to Watch After Johnson & Johnson's Earnings Beat

NextEra Energy

Sometimes stocks go on sale, and it's up to you to decide whether to bite. CRISPR Therapeutics is on the verge of what could be its first major success.

News for CRISPR Therapeutics Stock (CRSP)